| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0006-2952(93)90014-N |
| P698 | PubMed publication ID | 8512586 |
| P2093 | author name string | L Mathews | |
| J J McCormack | |||
| G Zon | |||
| A L Moore | |||
| R F Branda | |||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2037-2043 | |
| P577 | publication date | 1993-05-01 | |
| P1433 | published in | Biochemical Pharmacology | Q864229 |
| P1476 | title | Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1 | |
| P478 | volume | 45 |
| Q34368468 | 'Immunomers'--novel 3'-3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents |
| Q33716825 | A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif |
| Q37202396 | A role for NF-kappaB-dependent gene transactivation in sunburn. |
| Q39770135 | Activation of human B cells by phosphorothioate oligodeoxynucleotides |
| Q77296867 | Activation of spleen lymphocytes by plasmid DNA |
| Q71475786 | Amplification of antibody production by phosphorothioate oligodeoxynucleotides |
| Q41079010 | An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. |
| Q64274488 | Anti-Niemann Pick C1 Single-Stranded Oligonucleotides with Locked Nucleic Acids Potently Reduce Ebola Virus Infection In Vitro |
| Q73488155 | Antisense c-mycInhibition of Lymphoma Growth |
| Q77297328 | Antisense therapeutics |
| Q33826614 | Antisense therapeutics: is it as simple as complementary base recognition? |
| Q33683211 | Bacterial CpG DNA activates immune cells to signal infectious danger. |
| Q78862440 | CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents |
| Q38331783 | CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation |
| Q33767857 | DNA and a CpG oligonucleotide derived from Babesia bovis are mitogenic for bovine B cells |
| Q34980516 | Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles |
| Q35896079 | Identification and characterization of a cell membrane nucleic acid channel |
| Q41182494 | Immune activation by bacterial DNA: a new genetic code |
| Q73867128 | Immunostimulatory activity of CpG containing phosphorothioate oligodeoxynucleotide is modulated by modification of a single deoxynucleoside |
| Q74613271 | Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosphonate linkages |
| Q33601167 | Immunostimulatory properties of phosphorothioate CpG DNA containing both 3'-5'- and 2'-5'-internucleotide linkages |
| Q33916110 | Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides |
| Q41441257 | In vivo studies with antisense oligonucleotides |
| Q33916129 | Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides |
| Q34552661 | Medicinal chemistry and therapeutic potential of CpG DNA. |
| Q71820073 | Modulation of oligonucleotide-induced immune stimulation by cyclodextrin analogs |
| Q35864900 | Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications |
| Q34164404 | Plasmacytoid dendritic cells: the key to CpG. |
| Q53959438 | Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties. |
| Q73190812 | Preclinical antisense DNA therapy of cancer in mice |
| Q85118698 | Preclinical toxicity and toxicokinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase R2 |
| Q36437573 | Prevention of tumor formation in a mouse model of Burkitt's lymphoma by 6 weeks of treatment with anti-c-myc DNA phosphorothioate. |
| Q90431791 | Recent advancements in exon-skipping therapies using antisense oligonucleotides and genome editing for the treatment of various muscular dystrophies |
| Q53860033 | Secondary structures in CpG oligonucleotides affect immunostimulatory activity. |
| Q35544152 | Sequence-independent induction of Sp1 transcription factor activity by phosphorothioate oligodeoxynucleotides |
| Q34005422 | Signal transduction induced by immunostimulatory CpG DNA. |
| Q30829935 | Site of chemical modifications in CpG containing phosphorothioate oligodeoxynucleotide modulates its immunostimulatory activity |
| Q34005403 | The response of human B lymphocytes to oligodeoxynucleotides |
Search more.